Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58409 | 0.82 | — | — | |
| SCHEMBL18095586 | 0.82 | — | — | |
| SCHEMBL16033448 | 0.82 | — | — | |
| SCHEMBL11585608 | 0.79 | — | — | |
| SCHEMBL5727888 | 0.72 | PTGS1 (0.44) | PTGS1SLC7A11ANPEPENPEPALDH1A1 | |
| SCHEMBL9878917 | 0.70 | — | — | |
| Cystine SCHEMBL15667872 | 0.69 | PTGS1 (0.58) | PTGS1SLC7A11ENPEPALDH1A1 | |
| SCHEMBL23777960 | 0.69 | DPP4 (0.40) | PTGS1SLC7A11ENPEPALDH1A1MAPT | |
| SCHEMBL16590594 | 0.69 | PTGS1 (0.50) | PTGS1SLC7A11ANPEPENPEPALDH1A1 | |
| SCHEMBL12229214 | 0.69 | PTGS1 (0.50) | PTGS1SLC7A11ANPEPENPEPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645454-B2 | Antibody or antibody fragment which binds specifically to a normal or transformed PSA glycan or glycopeptide | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060223744-A1 | Antibody or antibody fragment which binds specifically to a normal or transformed PSA glycan or glycopeptide | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2006-10-05 | — | — | US | disclosed |
| EP-1570056-A2 | PROSTATE SPECIFIC ANTIGENS, CONJUGATES THEREOF, METHODS FOR THEIR PREPARATION AND USES THEREOF. | Sloan-Kettering Institute For Cancer Research (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004060915-A2 | PROSTATE SPECIFIC ANTIGENS, CONJUGATES THEREOF, METHODS FOR THEIR PREPARATION AND USES THEREOF. | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223744-A1 | Antibody or antibody fragment which binds specifically to a normal or transformed PSA glycan or glycopeptide | KLK3, MAN2B2, PA2G4 | PTGS1 4469/4885SLC7A11 3013/4885ANPEP 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.